Jump to content
helplinedonate

Tamara

Members
  • Content Count

    34
  • Joined

  • Last visited

Community Reputation

2 Neutral

About Tamara

  • Rank
    Advanced Member

Recent Profile Visitors

925 profile views
  1. Tamara

    Starting Isradipine

    Hi Adam! How are you now? Do you take isradipine now and what progress do you have? Thank you
  2. Tamara

    heavy legs

    Smalltownguy, hello! thank you for your attention ! it is like Lahdedah described like a walk in the sand. Maybe it's a kind of freeze of gait. I'm only looking for suggestions tamara
  3. Tamara

    heavy legs

    Yes, Lahdedah, it is like you describe - like a walk in the water or in the sand , mirapexine doesn't work at all, also like ldopa... please let me know if you will have any sort of information what helps in this condition! have a good day Tamara
  4. Tamara

    heavy legs

    Thank you, Lad
  5. Tamara

    heavy legs

    Good day for everybody! We need your help - advice !!! A man is suffering from PD for 8 years. Especially hard with the walk - walking - heaviness in the legs, feeling on the legs as hard weights, after taking pramipexole can not walk - legs do not listen, as if paralyzed takes levodopa azilekt and pramipexol 2.5 mg Advise, there can be someone was in such situation? what helped? what drugs are used to improve gait. Thanks to everyone.
  6. Tamara

    Mannitol

    Thank you, I havé searched but no results so I decided it is New idea
  7. Tamara

    Mannitol

    Hi everybody! Have you ever heard about MANNITOL . What do you think about it?
  8. Good news from science daily.com Northwestern Medicine scientists have identified a toxic cascade that leads to neuronal degeneration in patients with Parkinson's disease (PD) and figured out how to interrupt it, reports a study to be published September 7 in the journal Science. Intervening with an antioxidant early in the disease process may break the degenerative cycle and improve neuron function in PD, the study showed. The scientists also discovered that mouse models of PD didn't have the same abnormalities they found in human PD neurons, revealing the importance of studying human neurons to develop new therapies. Dr. Dimitri Krainc, the Aaron Montgomery Ward Professor and chair of neurology at Northwestern University Feinberg School of Medicine, is the study senior author. Lena Burbulla, a postdoctoral fellow in Krainc's laboratory, is first author. The research was started about six years ago in Krainc's lab at Massachusetts General Hospital and Harvard Medical School and was completed in the last four years at Feinberg. PD is the second most common neurodegenerative disorder, primarily caused by the death of dopamine-containing neurons in the substantia nigra, a region of the brain involved in motor control. While people naturally lose dopamine neurons as they age, patients with PD lose a much larger number of these neurons and the remaining cells are no longer able to compensate. Understanding how and why these neurons die is an important step in identifying treatments, Krainc said. While previous research indicated that the cellular mechanism behind the cell death involved the mitochondria and lysosomes, how these two pathways converge in dopamine neurons to cause cell death remained unknown up until now. Using human neurons from Parkinson's patients, Krainc and colleagues identified a toxic cascade of mitochondrial and lysosomal dysfunction initiated by an accumulation of oxidized dopamine and a protein called alpha-synuclein. Specifically, the current study demonstrated that an accumulation of oxidized dopamine depressed the activity of lysosomal glucocerebrosidase (GCase), an enzyme implicated in PD. That depression in turn weakened overall lysosomal function and contributed to degeneration of neurons. The accretion of oxidized dopamine didn't just interfere with lysosomes, however. Krainc and his colleagues discovered that the dopamine also damaged the neurons' mitochondria by increasing mitochondrial oxidant stress. These dysfunctional mitochondria led to increased oxidized dopamine levels, creating a vicious cycle. "The mitochondrial and lysosomal pathways are two critical pathways in disease development," said Krainc, who also is the director of the Center for Rare Neurological Diseases and a professor of neurological surgery and of physiology. "Combined with the alpha-synuclein accumulation, this study links the major pathological features of PD." Once they had catalogued this toxic cascade, Krainc and his colleagues began looking for ways to interrupt it. "One of the key strategies that worked in our experiments is to treat dopamine neurons early in the toxic cascade with specific antioxidants that improve mitochondrial oxidant stress and lower oxidized dopamine," Krainc said. "With this approach, we found that we can attenuate or prevent the downstream toxic effects in human dopaminergic neurons." This approach to interrupting the toxic cascade of oxidized dopamine may provide a target for the development of future therapies. However, identifying patients or subjects with early-stage neurodegeneration can be difficult, because damage has often occurred far before any symptoms are apparent, according to Krainc. Consequently, genetic testing will be central to future diagnostic efforts. Causative genes are prime candidates for screening, while risk genes such as GBA1 are less conclusive but still important markers, Krainc said. Early detection will also rely on brain imaging and other clinical signifiers. Interestingly, when compared to human cellular models, mouse models of PD did not demonstrate the same toxic cascade, according to the study. Krainc and his colleagues showed this is due to differences in metabolism of dopamine between species, and underscored the importance of studying human neurons to discover new targets for drug development. Story Source: Materials provided by Northwestern University. Original written by Marla Paul. Note: Content may be edited for style and length.
  9. Hi all! Has anybody seen this web http://pdrecovery.org/updates-latest-research/ what do you think about this ?
  10. Tamara

    Bad mornings

    Hi everybody! I need help.... In the mornings until 3-4 o'clock in the afternoon I feel bad and by the evening it's much more better. why is that? And another phenomenon. At home and in familiar rooms I do not walk well, and on the street at work in unfamiliar places it's good. How to overcome this home Lameness. I ask you for advice. Thank you.
  11. Dear friends! What do you think about it? Has anybody tried? ttps://www.gondola-parkinson.com/what-is-gondola/ GONDOLA® is a portable medical device for personal use, made for people who live with Parkinson’s, it is effective in treating Freezing of Gait, in reducing motor symptoms and in improving balance. The GONDOLA® device gives a treatment named “Automated Mechanical Peripheral Stimulation” (AMPS). Several clinical studies have documented that AMPS therapy is effective in improving motor skills in Parkinson’s: Freezing of Gait, slowness of movement, small steps and balance problems. AMPS therapy is based on non-invasive stimulations given via controlled mechanical impulses in specific areas of both feet; these stimulations induce an increased connectivity between brain areas involved in control of movement, as it has been documented in a clinical study published in the scientific journal PlosOne. GONDOLA® supplies the AMPS treatment in an individual way for each person (find out how it works) thanks to a configuration made by specialized personnel according to the different characteristics and needs of each patient; in this way, after having seen the positive response to the treatment, patients can continue the therapy directly at home with their personal device, maintaining so the benefits over time. Thanks to a significant, immediate decrease of the Freezing of Gait, to the improvement of the walking speed, to a better quality of walking, and to an improved balance, patients gain more self-confidence and improve their autonomy, being able to live a more independent life and to have better social and working lives; all this allows an improvement to the quality of life of the patient and of his whole family. The GONDOLA® medical device has been developed by Gondola Medical Technologies SA, a Swiss company specialized in research and development of new technologies for neurological rehabilitation. GONDOLA is distributed directly by Gondola Medical Technologies SA. Patients need to verify their response to the treatment given via the device by setting an appointment with a specialized GONDOLA operator. thank you for yours comments!
  12. Tamara

    Mucuna Pruiens

    Hi! It is not doctors advice. Doctors ignore mucuna and fava beans, they reccomend only drugs))) I decided myself and found this dosage. Very small. I have never tried fava beans. You can also try coffein and curcumin in curcubrain. It really helps.
  13. Tamara

    Mucuna Pruiens

    Hi! I use macuna Ldopa by NOW 15% . I am taking it from october 2016 NOW macuna l-dopa capsules 15% 4-5 capsules during a day + mirapexin 0,7/3 times a day + PKMERZ amantadin 1mg/3times and feel good dz 2012 by datscan , first simptoms -2008 , no tremor femail 50 years old 6 months ago stop azilect because of feelling baD have a nice day! Tamara
  14. Tamara

    Levadopa/carbidopa and pregnancy

    Dear Lenamegun thank you very much. It is very useful. There are no information on this subject.
×